Lisinopril prevents bullous pemphigoid induced by dipeptidyl peptidase 4 inhibitors via the Mas receptor pathway

Lisinopril prevents bullous pemphigoid induced by dipeptidyl peptidase 4 inhibitors via the Mas receptor pathway

Recent studies have suggested that dipeptidyl peptidase 4 (DPP4) inhibitors increase the risk of development of bullous pemphigoid (BP), which is the most common autoimmune blistering skin disease; however, the associated mechanisms remain unclear, and thus far, no therapeutic targets responsible fo...

Full description

Bibliographic Details
Main Authors: Keisuke Nozawa, Takahide Suzuki, Gen Kayanuma, Hiroki Yamamoto, Kazuki Nagayasu, Hisashi Shirakawa, Shuji Kaneko
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Immunology
Subjects:
bullous pemphigoid
dipeptidyl peptidase 4 inhibitor
lisinopril
Mas receptor
FDA Adverse Event Reporting System
IBM® MarketScan® Research databases
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1084960/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1084960/full

Similar Items